Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura K, Suzuki K, Imaoka T, Baba D, Suzuki M, Sampetrean O, Saya H, Ichimura K, Kitabayashi I. Machida Y, et al. Among authors: katsumoto t. Mol Cancer Ther. 2020 Feb;19(2):375-383. doi: 10.1158/1535-7163.MCT-18-1349. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727689
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M, Fujita S, Katsumoto T, Yamagata K, Ogawara Y, Hattori A, Kagiyama Y, Honma D, Araki K, Inoue T, Kato A, Inaki K, Wada C, Ono Y, Yamamoto M, Miura O, Nakashima Y, Kitabayashi I. Nakagawa M, et al. Among authors: katsumoto t. Cancer Sci. 2019 Jan;110(1):194-208. doi: 10.1111/cas.13840. Epub 2018 Nov 16. Cancer Sci. 2019. PMID: 30343511 Free PMC article.
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, Machida Y, Katsumoto T, Yamagata K, Hattori A, Fujita S, Aikawa Y, Ishikawa T, Soga T, Kawai A, Chuman H, Yokoyama N, Fukushima S, Yahiro K, Kimura A, Shimada E, Hirose T, Fujiwara T, Setsu N, Matsumoto Y, Iwamoto Y, Nakashima Y, Kitabayashi I. Nakagawa M, et al. Among authors: katsumoto t. Oncogene. 2019 Oct;38(42):6835-6849. doi: 10.1038/s41388-019-0929-9. Epub 2019 Aug 12. Oncogene. 2019. PMID: 31406254
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, Honma D, Adachi N, Araki K, Kato A, Inaki K, Ono Y, Fukuhara S, Kobayashi Y, Tobinai K, Kitabayashi I. Kagiyama Y, et al. Among authors: katsumoto t. Cancer Sci. 2021 Jun;112(6):2314-2324. doi: 10.1111/cas.14905. Epub 2021 May 1. Cancer Sci. 2021. PMID: 33792119 Free PMC article.
[Transcriptional regulation].
Katsumoto T, Kitabayashi I. Katsumoto T, et al. Nihon Rinsho. 2012 Apr;70 Suppl 2:75-8. Nihon Rinsho. 2012. PMID: 23133931 Free article. Japanese. No abstract available.
MLL is essential for NUP98-HOXA9-induced leukemia.
Shima Y, Yumoto M, Katsumoto T, Kitabayashi I. Shima Y, et al. Among authors: katsumoto t. Leukemia. 2017 Oct;31(10):2200-2210. doi: 10.1038/leu.2017.62. Epub 2017 Feb 17. Leukemia. 2017. PMID: 28210005
122 results